LUNGevity Foundation announced the recipients of its 2018 Career Development Awards for lung cancer research. These awards fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity's prestigious Scientific Advisory Board.
bluebird bio, Inc. and Gritstone Oncology Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
JNCCN—Journal of the National Comprehensive Cancer Network– introduced new associate editors, who reflect the journal's growing focus on original research designed to improve the quality of cancer care delivery, worldwide. The expanding focus on original research is led by editor-in-chief Margaret Tempero, professor of medicine and Director of the UCSF Pancreas Center at UCSF Helen Diller Family Comprehensive Cancer Center.
Steven Rosenberg, Carl June and James Allison received the 2018 Albany Medical Center Prize in Medicine and Biomedical Research.xxx:moreRosenberg is chief of the surgery branch a
Karen Knudsen, enterprise director of the Sidney Kimmel Cancer Center–Jefferson Health, was elected vice president/president-elect of the Association of American Cancer Institutes' board of directors.
Cory Wiegert was named chief executive officer of CancerLinQ LLC, a non-profit subsidiary of the American Society of Clinical Oncology.
Moffitt Cancer Center's chief information security officer will join a group of experts charged with protecting and enhancing national cybersecurity.
Exact Sciences Corp. and Pfizer Inc. announced an agreement through 2021 to co-promote Cologuard, the only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join the Exact Sciences sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign.
MD Anderson Cancer Center and Accelerator Life Science Partners announced the launch of Magnolia Neurosciences Corp., a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson's Therapeutics Discovery division, including the Institute for Applied Cancer Science and the Neurodegeneration Consortium.
Members of the UCLA urology department received $9.3 million of funding from the state of California to help combat the financial burden of cancer treatment for men diagnosed with prostate cancer.
